Highlights • FY08 result ahead of EBITDA guidance • Underlying earnings per share accretion • $463 million iSOFT acquisition and integration completed • Integration synergies in excess of $27 million from FY09 • Revenue base transformed o Annualised group revenues - $472 million o Over 80% of group revenues are now sourced from operations outside of Australia and South East Asia. o Over 80% of FYO9 revenues are recurring, contracted or expected. • Global launch of LORENZO in FY09 • Outlook guidance of 18% revenue growth on the annualised revenue base IBA Health Group has recorded revenues of $361 million, up 381% (FY07 $75 million), and an underlying EBITDA of $106 million, up 232% (FY07 $32 million), reflecting the eight-month contribution from iSOFT which was acquired in November 2007. The reported NPAT of $14.4 million includes significant items of $35 million (comprising amortisation of intangibles on acquisition, integration and one-off acquisition costs and impairment charges), making an underlying NPAT of $49 million, up 113% (FY07 $23 million) against FY07.
IBA Price at posting:
0.0¢ Sentiment: None Disclosure: Held